Hepatitis C Virus RNA Levels During Initial Induction or Standard Interferon Therapy: Influence of Continued Treatment on Sustained Response

References

• Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358: 1241–2.
   Google Scholar
• Carlsson T, Weiland O, Reichard O. Viral kinetics and treatment response in patients with hepatitis C during induction and standard therapy in combination with ribavirin. Scand J Gastroenterol 2002; 37: 1228–34.
   Google Scholar
• Neumann A, Dahari H, Conrad A, Pianko S, McHutchinson J. Early prediction and mechanism of the ribavirin/INF-alfa dual therapy effect on chronic hepatitis C virus (HCV) infection. Hepatology 1999; 30(Suppl): 309A.
   Google Scholar
• Neumann A, Lam N, Dahari H, Davidian M, Wiley T, Mika B, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28–35.
   PubMed Web of Science ®Google Scholar
• Carlsson T, Reichard O, Weiland O. Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy. Scand J Infect Dis 2001; 33: 838–42.
   Google Scholar
• Balciuniene L, Ambrozaitis A, Weiland O. Viral kinetics during induction versus standard alfa interferon mono-therapy in Lithuanian patients with chronic hepatitis C virus infection. Acta Med Lituan 2002; 9: 182–9.
   Google Scholar
• Reichard O, Norkrans G, Frydén A, Braconier J, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83–7.
   Google Scholar
• Poynard T, Marcelin P, Lee S, Niederau C, Minuk G, Ideo G, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.
   PubMed Web of Science ®Google Scholar
• McHutchison J, Gordon S, Schiff E, Schiffman M, Lee W, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92.
   PubMed Web of Science ®Google Scholar
• Fried M, Shiffman M, Reddy K, Smith C, Marinos G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
   PubMed Web of Science ®Google Scholar
• Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006–11.
   PubMed Web of Science ®Google Scholar
• Bjoro K, Bell H, Myrvang B, Skaug K, Raknerud N, Sandvei P, et al. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study. Scand J Gastroenterol 2002; 37: 344–9.
   Web of Science ®Google Scholar
• Bjoro K, Bell H, Hellum K, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37: 226–32.
   PubMed Web of Science ®Google Scholar
• Pawlotsky J, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654–9.
   PubMed Web of Science ®Google Scholar
• Doglio A, Laffont C, Caroli-Bosc F, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999; 37: 1567–9.
   Google Scholar
• Stuyver L, Wyseur A, van AW, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259–66.
   Google Scholar
• Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–9.
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6: 237–42.
   PubMed Web of Science ®Google Scholar
• Batts K, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409–17.
   PubMed Web of Science ®Google Scholar
• Di Marco V, Ferraro D, Almasio P, Vaccaro A, Parisi P, Cappello M, et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. J Viral Hepat 2002; 9: 354–9.
   Google Scholar
• Lau J, Tam R, Liang T, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002–9.
   PubMed Web of Science ®Google Scholar
• Hultgren C, Milich D, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 2381–91.
   PubMed Web of Science ®Google Scholar
• Tam R, Pai B, Bard J, Lim C, Averett D, Phan U, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30: 376–82.
   PubMed Web of Science ®Google Scholar
• Crotty S, Cameron C, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001; 98: 6895–900.
   Google Scholar
• Crotty S, Cameron C, Andino R. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002; 80: 86–95.
   Google Scholar
• Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591–8.
   PubMed Web of Science ®Google Scholar
• Saracco G, Ciancio A, Olivero A, Smedile A, Roffi L, Croce G, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001; 34: 133–8.
   Google Scholar
• Zeuzem S, Herrmann E, Lee J, Fricke J, Neumann A, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438–47.
   PubMed Web of Science ®Google Scholar